Administration Routes The administration route significantly impacts the pharmacokinetics of GLP-1 receptor agonists by influencing the rate and extent of drug absorption, onset of action, bioavailability, and overall exposure
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
Your Partner in Optimal Health Established Expertise Trusted Since 2016 Proven Outcomes Results You Can Measure Personalized Treatment Tailored to You Revived Wellness : Houston's Leading TPE, Peptide & Regenerative Clinic Welcome to Revived Personalized Wellness, your trusted partner in optimal health
Named for its research focus on tissue recovery, this blend pairs two of the most extensively studied repair-associated peptides in a single formulation
